Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046864 · ClinicalTrials.gov registry record · Phase 1
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT01046864 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants.
The verdict
NCT01046864, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.
Interventions
- DRUG Leucovorin
- DRUG Irinotecan
- DRUG 5-FU
- DRUG Brivanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01046864
The ClinicalTrials.gov registry entry for NCT01046864 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT01046864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01046864 about?
NCT01046864 is a clinical study titled "Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)". The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.
What is the current status of trial NCT01046864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2010-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01046864?
The interventions under investigation include: Leucovorin (DRUG), Irinotecan (DRUG), 5-FU (DRUG), Brivanib (DRUG).
Who is sponsoring clinical trial NCT01046864?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.